Abstract
Abstract The presentation will focus genomics of high grade serous ovarian cancer (HGSC). I will briefly describe TRACEBACK, a study aimed at identifying deceased high-risk mutation carriers, and how a novel approach to patient ascertainment and testing may serve as a model for other familial cancer diseases. I will discuss some of key questions and directions arising from our studies of end-stage BRCA-related HGSC using samples collected through a rapid autopsy program. The major focus of the presentation will be on analyses of patients with exceptionally poor or favorable overall survival, including a cohort of BRCA1/2 patients with an unusually poor response to treatment and survival, and HGSC patients who survive more than 10 years following their diagnosis. Citation Format: David D. Bowtell. Placing our bets to make a difference [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr IA001.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
